There is IMHO NO possibility that this will be delisted, All that Bgmd has to do is show nasdaq that they have been cleared by the FDA for the galectin 3 test with Abbott's automated immunoassay test and they will be granted another 180 extension, DONE DEAL
The acquisition of Veropharm is a strategic move for the company's Established Pharmaceutical division, especially since it allows it to expand its footprint into Russia, a key emerging market for the company. The acquisition has also given Abbott access to machines that serves Abbott's areas of focus very well. The company's Diagnostic's division is also poised for future growth on the back of FDA clearance for its galectin-3 test that can be used on the ARCHITECT platform.
0.001, P = 0.002, respectively. In case of cirrhotic patients, galectin-3 levels were significantly higher in patients with cirrhosis secondary to HCV compared with HBV P = 0.03. When we evaluated galectin-3 levels in HCC patients, it was found to be 3.92 ng/mL in HCC secondary to hepatitis B and 5.37 ng/mL in HCC secondary to hepatitis C.
Serum galectin-3 levels in patients with chronic HBV or HCV may guide us about progression to cirrhosis or HCC and prognosis of the disease. Especially, galectin-3 levels may be more pronounced in case of HCV.
Galectins affect diverse physiological and pathophysiological processes such as development, inflammation, and tumor growth. We aimed to compare serum galectin-3 levels in three patient groups with chronic hepatitis B and C virus HBV, HCV, cirrhosis secondary to HBV or HCV, and hepatocellular carcinoma HCC secondary to HBV or HCV and evaluate the role of galectin-3 during HCC progression.
PATIENTS AND METHODS:
Nineteen patients with hepatocellular cancer, 22 patients with cirrhosis, and 24 patients with chronic hepatitis B and C were included in this study. Serum galectin-3 levels in different liver diseases were assessed by enzyme-linked immunosorbent assay.
The mean galectin-3 levels were 4.61 ng/mL ±2.32 in HCC patients, 5.68 ng/mL ±2,2 in cirrhotic patients, 1.98 ng/mL ±1.50 in chronic viral hepatitis group. There were no statistical differences between HCC and cirrhotic patients P = 0.5, but lower in chronic hepatitis group statistically compared with cirrhosis and HCC P
Now. Which of these test would you use
Critical Diagnostics reported today that the U.S. Center for Medicare and Medicaid Services (CMS) has confirmed that the 2015 Medicare reimbursement for performing a ST2 test will be $29.93. This took effect January 1, 2015.
ST2 in serum or plasma by enzyme-linked immunosorbant assay (ELISA) in a microtiter plate format.
BG Medicine, reported today that the U.S. Center for Medicare and Medicaid Services (CMS) 2014 national limitation amount is $30.01.
( On December 29, 2014, the U.S. Food and Drug Administration (the “FDA”) made publicly available the 510(k) clearance for premarket notification number K140436, which represents the first automated version of galectin-3 testing to receive regulatory clearance in the United States. BG Medicine, Inc. (the “Company”) is the developer of the BGM Galectin-3® Test, which is the FDA-cleared manual microtiter plate version of the galectin-3 test, and the licensor of this first automated galectin-3 assay, which is used with the Abbott ARCHITECT® fully-automated immunoassay analyzer. The new assay will be commercialized through an agreement between BG Medicine and Abbott Laboratories. )
You decide - ST2 in serum or plasma by enzyme-linked immunosorbant assay (ELISA) in a microtiter plate format.
The First Automated version of galectin-3 testing to receive regulatory clearance in the United States. BG Medicine, Inc.
Days Or Minutes,, It up to you
THE PRESAGE® ASSAY
The Critical Diagnostics Presage® ST2 Assay kit is an in vitro diagnostic device that quantitatively measures ST2 in serum or plasma by enzyme-linked immunosorbant assay (ELISA) in a microtiter plate format. The Presage® ST2 Assay is indicated to be used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with heart failure.
(( Given the widespread utilization of the natriuretic peptides today, the clinical performance of novel markers must complement or exceed the existing tests. It is unlikely that a test with equivalent performance will be suﬃcient for clinical laboratories to make a replacement. It is also advantageous to have new biomarkers that are approved by the either the FDA or the European CE Marking, or both. Finally, it is most useful if tests are available on automated immunoassay analyzers. While research enzymelinked immunosorbent assays (ELISA) are acceptable and widely used for clinical trials, and the generation of research data and publications, ELISAs are not widely used by clinical laboratories. Alternatively, a test that is available on a point‐of‐care platform can be more readily acquired and put into use, even if the testing is conducted in the central laboratory by medical technologists
Galectin-3 as an Oncological Biomarker
Anyone with half a brain " not you " knows the connection between LJPC and BGMD, STICK to what you know, FXIT
Oh, thanks for keeping my post on top
We were talking about yesterday raise in price moron. You probably would be better off going back to your mainstay stock @ .01 FIXT,
La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension
Business Wire La Jolla Pharmaceutical Company
Feb 9, 2015 8:00 AM
SAN DIEGO--(BUSINESS WIRE)--
La Jolla Pharmaceutical Company (LJPC)
In April 2013 Seeking Alph Article = ( Abbott: Galectin-3 Assay Sees Approval And Builds Takeover Case For La Jolla Pharmaceuticals )
La Jolla Uses the BGM Galectin-3® Test. For GCS 100
( As of now, the only drug that inhibits Galectin-3 is GCS 100, a first-in-class Galectin-3 agonist ) This is La Jolla's
Ongoing research suggests that Galectin-3's role in various other diseases may be significant, as Galectin-3 overexpression has been shown to lead to fibrosis and scarring of tissue which leads to additional complications found in other indications, but La Jolla is limiting itself to the diseases/indications that have the strongest links to Galectin-3 overexpression. These include Chronic Kidney Disease (CKD), Chronic Liver Disease (cirrhosis), and cancer immunotherapy but not cardiovascular risk (possibly for strategic reasons).
Treatment of CKD has proven difficult, and the disease generally leads to poor outcomes and co-morbidities which is why CKD seems to be a particularly great indication for a first-in-class Galectin-3 inhibitor.
New studies suggest that Galectin-3 is a lot more important than we thought, and it may rise to prominence as a biomarker for cardiovascular risk (and other indications) due to the commercial availability of Abbott's Architect assay.
Abbott is a diversified company that has probably the best overall product line for diagnostic products, and may have a big winner with Architect due to the overall importance of Galectin-3.
After its failure with bardoxolone last year, Abbott may be looking for another way to develop a CKD treatment. La Jolla happens to have the only Galectin-3 inhibitor in clinical development, which synergizes not only with Abbott's presumed desire to play the CKD treatment market but with newly launched Architect assay which should help boost the overall profile of Galectin 3
La Jolla Pharmaceutical Company Reports Positive, Top-Line Results from Phase 2 Clinical Trial of GCS-100 in Chronic Kidney Disease
La Jolla uses BGMD Galectin 3 Test
This from March 12. 2014 PR by La Jolla ( LJPC )
( The trial met its primary efficacy endpoint of improvement in kidney function, as well as key secondary endpoints including a statistically significant reduction in circulating levels of galectin-3, the molecular target of GCS-100, at the effective therapeutic dose, as measured using the BGM Galectin-3® Test. )
Take a walk with your 2k shares,
Oh BTW did Yahoo security get back to you yet, If not , They will !!!!!
A new study shows that galectin-3 is a member of the glycoprotein family. Galectin-3 is 30 kDa, contains a carbohydrate-recognition-binding domain of 130 amino acids that change the precise binding of β-galactosides. Galectin-3 is expressed in the nucleus, cytoplasm, organelle, cell surface, and extracellular area. Galectin-3 is also used as a biomarker to identify at risk individuals, and predict patient response to different medication and therapies. for example, galectin-3 levels can be employed in early detection of failure-prone hearts.
Galectin-3 overexpression promotes growth transformation and also the maintenance of reworked phenotypes likewise as enhances the neoplasm cell's adhesion to the extracellular matrix and increase pathologic process spreading. Galectin-3 will be either a restrictive or a promoting apoptotic counting on its sub-cellular localization. In immune regulation, galectin-3 will regulate immune cell activities and helps contribute to the neoplasm cell's evasion of the system. Galectin-3 also helps promote ontogenesis. Galectin-3 is upregulated in patients with disorder pulmonic pathology. The cells that receive galectin-3 stimulation upregulated the formation of pathology and albuminoid formation. The pathology is important in several aspects of intrabody regeneration. The heart muscle lining perpetually undergoes necessary pathology, and the inhibition of galectin-3 interferes with heart muscle fibrogenesis.
DO YOU KNOW HOW TO READ ??????
This is from the 3Q 2014, Not my words, These are the words of the CEO of BGMD
From Q3 2014 " Company believes that its existing cash will be sufficient to fund its operations and service its debt into the second quarter of 2015. Until the Company generates significant product revenues to reach cash breakeven, the Company will need to raise additional funds to finance its operations and service its existing debt through the second quarter of 2015 and beyond. ""
(( into the second quarter of 2015. ))
(( Company will need to raise additional funds to finance its operations and service its existing debt through the second quarter of 2015 and beyond. )) THAT MEANS THEY DONT HAVE ENOUGH CASH TO GET THRU THE 2nd QUARTER